annual total liabilities:
$138.94M+$11.14M(+8.72%)Summary
- As of today (May 29, 2025), RNA annual total liabilities is $138.94 million, with the most recent change of +$11.14 million (+8.72%) on December 31, 2024.
- During the last 3 years, RNA annual total liabilities has risen by +$92.79 million (+201.05%).
- RNA annual total liabilities is now -14.38% below its all-time high of $162.26 million, reached on December 31, 2019.
Performance
RNA Total liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly total liabilities:
$130.35M-$8.58M(-6.18%)Summary
- As of today (May 29, 2025), RNA quarterly total liabilities is $130.35 million, with the most recent change of -$8.58 million (-6.18%) on March 31, 2025.
- Over the past year, RNA quarterly total liabilities has increased by +$9.78 million (+8.11%).
- RNA quarterly total liabilities is now -19.67% below its all-time high of $162.26 million, reached on December 31, 2019.
Performance
RNA quarterly total liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Total liabilities Formula
Total Liabilities = Current Liabilities + Long-Term Liabilities
RNA Total liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +8.7% | +8.1% |
| 3 y3 years | +201.1% | +186.9% |
| 5 y5 years | -14.4% | +388.6% |
RNA Total liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +201.1% | -6.2% | +186.9% |
| 5 y | 5-year | -14.4% | +402.0% | -6.2% | +420.2% |
| alltime | all time | -14.4% | +402.0% | -19.7% | +420.2% |
RNA Total liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2025 | - | $130.35M(-6.2%) |
| Dec 2024 | $138.94M(+8.7%) | $138.94M(+1.1%) |
| Sep 2024 | - | $137.39M(+8.7%) |
| Jun 2024 | - | $126.39M(+4.8%) |
| Mar 2024 | - | $120.58M(-5.6%) |
| Dec 2023 | $127.79M(+110.4%) | $127.79M(+129.4%) |
| Sep 2023 | - | $55.70M(+7.9%) |
| Jun 2023 | - | $51.61M(-6.3%) |
| Mar 2023 | - | $55.06M(-9.3%) |
| Dec 2022 | $60.73M | $60.73M(+13.4%) |
| Sep 2022 | - | $53.56M(+15.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2022 | - | $46.45M(+2.3%) |
| Mar 2022 | - | $45.43M(-1.6%) |
| Dec 2021 | $46.15M(+66.8%) | $46.15M(+48.7%) |
| Sep 2021 | - | $31.04M(+19.2%) |
| Jun 2021 | - | $26.04M(-9.1%) |
| Mar 2021 | - | $28.64M(+3.5%) |
| Dec 2020 | $27.68M(-82.9%) | $27.68M(+6.6%) |
| Sep 2020 | - | $25.97M(+3.6%) |
| Jun 2020 | - | $25.06M(-6.1%) |
| Mar 2020 | - | $26.68M(-83.6%) |
| Dec 2019 | $162.26M(+259.7%) | $162.26M |
| Dec 2018 | $45.11M | - |
FAQ
- What is Avidity Biosciences annual total liabilities?
- What is the all time high annual total liabilities for Avidity Biosciences?
- What is Avidity Biosciences annual total liabilities year-on-year change?
- What is Avidity Biosciences quarterly total liabilities?
- What is the all time high quarterly total liabilities for Avidity Biosciences?
- What is Avidity Biosciences quarterly total liabilities year-on-year change?
What is Avidity Biosciences annual total liabilities?
The current annual total liabilities of RNA is $138.94M
What is the all time high annual total liabilities for Avidity Biosciences?
Avidity Biosciences all-time high annual total liabilities is $162.26M
What is Avidity Biosciences annual total liabilities year-on-year change?
Over the past year, RNA annual total liabilities has changed by +$11.14M (+8.72%)
What is Avidity Biosciences quarterly total liabilities?
The current quarterly total liabilities of RNA is $130.35M
What is the all time high quarterly total liabilities for Avidity Biosciences?
Avidity Biosciences all-time high quarterly total liabilities is $162.26M
What is Avidity Biosciences quarterly total liabilities year-on-year change?
Over the past year, RNA quarterly total liabilities has changed by +$9.78M (+8.11%)